Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 445 to 453 of 453 entries
Sorted by: Best Match Show Resources per page
Branch Retinal Artery Occlusion with Prepapillary Macroaneurysm Enlargement.

Ophthalmology. Retina

Kakihara S, Kurenuma T, Murata T.
PMID: 34752305
Ophthalmol Retina. 2021 Nov;5(11):1124. doi: 10.1016/j.oret.2021.08.003.

No abstract available.

Cite
Kakihara S, Kurenuma T, Murata T. Branch Retinal Artery Occlusion with Prepapillary Macroaneurysm Enlargement. Ophthalmol Retina. 2021;5(11):1124doi: 10.1016/j.oret.2021.08.003.
Kakihara, S., Kurenuma, T., & Murata, T. (2021). Branch Retinal Artery Occlusion with Prepapillary Macroaneurysm Enlargement. Ophthalmology. Retina, 5(11), 1124. https://doi.org/10.1016/j.oret.2021.08.003
Kakihara, Shinji, et al. "Branch Retinal Artery Occlusion with Prepapillary Macroaneurysm Enlargement." Ophthalmology. Retina vol. 5,11 (2021): 1124. doi: https://doi.org/10.1016/j.oret.2021.08.003
Kakihara S, Kurenuma T, Murata T. Branch Retinal Artery Occlusion with Prepapillary Macroaneurysm Enlargement. Ophthalmol Retina. 2021 Nov;5(11):1124. doi: 10.1016/j.oret.2021.08.003. PMID: 34752305.
Copy Download .nbib Format: NLM
Development of a genetically modified hepatoma cell line with heat-inducible high liver function.

Cytotechnology

Kitano H, Nagae Y, Kawabe Y, Ito A, Kamihira M.
PMID: 34149171
Cytotechnology. 2021 Jun;73(3):353-362. doi: 10.1007/s10616-021-00457-4. Epub 2021 Feb 24.

Hepatoma cells are a promising cell source for the construction of bioartificial liver (BAL) systems owing to their high proliferative capability. However, their low liver function compared with primary hepatocytes is a major problem. In a previous study, we...

Cite
Kitano H, Nagae Y, Kawabe Y, et al. Development of a genetically modified hepatoma cell line with heat-inducible high liver function. Cytotechnology. 2021;73(3):353-362doi: 10.1007/s10616-021-00457-4.
Kitano, H., Nagae, Y., Kawabe, Y., Ito, A., & Kamihira, M. (2021). Development of a genetically modified hepatoma cell line with heat-inducible high liver function. Cytotechnology, 73(3), 353-362. https://doi.org/10.1007/s10616-021-00457-4
Kitano, Hiroyuki, et al. "Development of a genetically modified hepatoma cell line with heat-inducible high liver function." Cytotechnology vol. 73,3 (2021): 353-362. doi: https://doi.org/10.1007/s10616-021-00457-4
Kitano H, Nagae Y, Kawabe Y, Ito A, Kamihira M. Development of a genetically modified hepatoma cell line with heat-inducible high liver function. Cytotechnology. 2021 Jun;73(3):353-362. doi: 10.1007/s10616-021-00457-4. Epub 2021 Feb 24. PMID: 34149171; PMCID: PMC8166997.
Copy Download .nbib Format: NLM
Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade.

iScience

Hama N, Kobayashi T, Han N, Kitagawa F, Kajihara N, Otsuka R, Wada H, Lee HK, Rhee H, Hasegawa Y, Yagita H, Baghdadi M, Seino KI.
PMID: 33205010
iScience. 2020 Sep 19;23(10):101584. doi: 10.1016/j.isci.2020.101584. eCollection 2020 Oct 23.

Interleukin-34 (IL-34) is an alternative ligand to colony-stimulating factor-1 (CSF-1) for the CSF-1 receptor that acts as a key regulator of monocyte/macrophage lineage. In this study, we show that tumor-derived IL-34 mediates resistance to immune checkpoint blockade regardless of...

Cite
Hama N, Kobayashi T, Han N, et al. Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade. iScience. 2020;23(10):101584doi: 10.1016/j.isci.2020.101584.
Hama, N., Kobayashi, T., Han, N., Kitagawa, F., Kajihara, N., Otsuka, R., Wada, H., Lee, H. K., Rhee, H., Hasegawa, Y., Yagita, H., Baghdadi, M., & Seino, K. I. (2020). Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade. iScience, 23(10), 101584. https://doi.org/10.1016/j.isci.2020.101584
Hama, Naoki, et al. "Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade." iScience vol. 23,10 (2020): 101584. doi: https://doi.org/10.1016/j.isci.2020.101584
Hama N, Kobayashi T, Han N, Kitagawa F, Kajihara N, Otsuka R, Wada H, Lee HK, Rhee H, Hasegawa Y, Yagita H, Baghdadi M, Seino KI. Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade. iScience. 2020 Sep 19;23(10):101584. doi: 10.1016/j.isci.2020.101584. eCollection 2020 Oct 23. PMID: 33205010; PMCID: PMC7648133.
Copy Download .nbib Format: NLM
PGE2 and Thrombin Induce Myofibroblast Transdifferentiation via Activin A and CTGF in Endometrial Stromal Cells.

Endocrinology

Kusama K, Fukushima Y, Yoshida K, Azumi M, Yoshie M, Mizuno Y, Kajihara T, Tamura K.
PMID: 34606582
Endocrinology. 2021 Dec 01;162(12). doi: 10.1210/endocr/bqab207.

Endometriosis is characterized by inflammation and fibrotic changes. Our previous study using a mouse model showed that proinflammatory factors present in peritoneal hemorrhage exacerbated inflammation in endometriosis-like grafts, at least in part through the activation of prostaglandin (PG) E2...

Cite
Kusama K, Fukushima Y, Yoshida K, et al. PGE2 and Thrombin Induce Myofibroblast Transdifferentiation via Activin A and CTGF in Endometrial Stromal Cells. Endocrinology. 2021;162(12)doi: 10.1210/endocr/bqab207.
Kusama, K., Fukushima, Y., Yoshida, K., Azumi, M., Yoshie, M., Mizuno, Y., Kajihara, T., & Tamura, K. (2021). PGE2 and Thrombin Induce Myofibroblast Transdifferentiation via Activin A and CTGF in Endometrial Stromal Cells. Endocrinology, 162(12), . https://doi.org/10.1210/endocr/bqab207
Kusama, Kazuya, et al. "PGE2 and Thrombin Induce Myofibroblast Transdifferentiation via Activin A and CTGF in Endometrial Stromal Cells." Endocrinology vol. 162,12 (2021). doi: https://doi.org/10.1210/endocr/bqab207
Kusama K, Fukushima Y, Yoshida K, Azumi M, Yoshie M, Mizuno Y, Kajihara T, Tamura K. PGE2 and Thrombin Induce Myofibroblast Transdifferentiation via Activin A and CTGF in Endometrial Stromal Cells. Endocrinology. 2021 Dec 01;162(12). doi: 10.1210/endocr/bqab207. PMID: 34606582.
Copy Download .nbib Format: NLM
Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes.

JAMA oncology

Goudie C, Witkowski L, Cullinan N, Reichman L, Schiller I, Tachdjian M, Armstrong L, Blood KA, Brossard J, Brunga L, Cacciotti C, Caswell K, Cellot S, Clark ME, Clinton C, Coltin H, Felton K, Fernandez CV, Fleming AJ, Fuentes-Bolanos N, Gibson P, Grant R, Hammad R, Harrison LW, Irwin MS, Johnston DL, Kane S, Lafay-Cousin L, Lara-Corrales I, Larouche V, Mathews N, Meyn MS, Michaeli O, Perrier R, Pike M, Punnett A, Ramaswamy V, Say J, Somers G, Tabori U, Thibodeau ML, Toupin AK, Tucker KM, van Engelen K, Vairy S, Waespe N, Warby M, Wasserman JD, Whitlock JA, Sinnett D, Jabado N, Nathan PC, Shlien A, Kamihara J, Deyell RJ, Ziegler DS, Nichols KE, Dendukuri N, Malkin D, Villani A, Foulkes WD.
PMID: 34617981
JAMA Oncol. 2021 Dec 01;7(12):1806-1814. doi: 10.1001/jamaoncol.2021.4536.

IMPORTANCE: Prompt recognition of a child with a cancer predisposition syndrome (CPS) has implications for cancer management, surveillance, genetic counseling, and cascade testing of relatives. Diagnosis of CPS requires practitioner expertise, access to genetic testing, and test result interpretation....

Cite
Goudie C, Witkowski L, Cullinan N, et al. Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA Oncol. 2021;7(12):1806-1814doi: 10.1001/jamaoncol.2021.4536.
Goudie, C., Witkowski, L., Cullinan, N., Reichman, L., Schiller, I., Tachdjian, M., Armstrong, L., Blood, K. A., Brossard, J., Brunga, L., Cacciotti, C., Caswell, K., Cellot, S., Clark, M. E., Clinton, C., Coltin, H., Felton, K., Fernandez, C. V., Fleming, A. J., Fuentes-Bolanos, N., Gibson, P., Grant, R., Hammad, R., Harrison, L. W., Irwin, M. S., Johnston, D. L., Kane, S., Lafay-Cousin, L., Lara-Corrales, I., Larouche, V., Mathews, N., Meyn, M. S., Michaeli, O., Perrier, R., Pike, M., Punnett, A., Ramaswamy, V., Say, J., Somers, G., Tabori, U., Thibodeau, M. L., Toupin, A. K., Tucker, K. M., van Engelen, K., Vairy, S., Waespe, N., Warby, M., Wasserman, J. D., Whitlock, J. A., Sinnett, D., Jabado, N., Nathan, P. C., Shlien, A., Kamihara, J., Deyell, R. J., Ziegler, D. S., Nichols, K. E., Dendukuri, N., Malkin, D., Villani, A., & Foulkes, W. D. (2021). Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA oncology, 7(12), 1806-1814. https://doi.org/10.1001/jamaoncol.2021.4536
Goudie, Catherine, et al. "Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes." JAMA oncology vol. 7,12 (2021): 1806-1814. doi: https://doi.org/10.1001/jamaoncol.2021.4536
Goudie C, Witkowski L, Cullinan N, Reichman L, Schiller I, Tachdjian M, Armstrong L, Blood KA, Brossard J, Brunga L, Cacciotti C, Caswell K, Cellot S, Clark ME, Clinton C, Coltin H, Felton K, Fernandez CV, Fleming AJ, Fuentes-Bolanos N, Gibson P, Grant R, Hammad R, Harrison LW, Irwin MS, Johnston DL, Kane S, Lafay-Cousin L, Lara-Corrales I, Larouche V, Mathews N, Meyn MS, Michaeli O, Perrier R, Pike M, Punnett A, Ramaswamy V, Say J, Somers G, Tabori U, Thibodeau ML, Toupin AK, Tucker KM, van Engelen K, Vairy S, Waespe N, Warby M, Wasserman JD, Whitlock JA, Sinnett D, Jabado N, Nathan PC, Shlien A, Kamihara J, Deyell RJ, Ziegler DS, Nichols KE, Dendukuri N, Malkin D, Villani A, Foulkes WD. Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA Oncol. 2021 Dec 01;7(12):1806-1814. doi: 10.1001/jamaoncol.2021.4536. PMID: 34617981; PMCID: PMC8498936.
Copy Download .nbib Format: NLM
Mosquito-Borne Viral Pathogens Detected in Zambia: A Systematic Review.

Pathogens (Basel, Switzerland)

Velu RM, Kwenda G, Libonda L, Chisenga CC, Flavien BN, Chilyabanyama ON, Simunyandi M, Bosomprah S, Sande NC, Changula K, Muleya W, Mburu MM, Mubemba B, Chitanga S, Tembo J, Bates M, Kapata N, Orba Y, Kajihara M, Takada A, Sawa H, Chilengi R, Simulundu E.
PMID: 34451471
Pathogens. 2021 Aug 10;10(8). doi: 10.3390/pathogens10081007.

Emerging and re-emerging mosquito-borne viral diseases are a threat to global health. This systematic review aimed to investigate the available evidence of mosquito-borne viral pathogens reported in Zambia. A search of literature was conducted in PubMed and Google Scholar...

Cite
Velu RM, Kwenda G, Libonda L, et al. Mosquito-Borne Viral Pathogens Detected in Zambia: A Systematic Review. Pathogens. 2021;10(8)doi: 10.3390/pathogens10081007.
Velu, R. M., Kwenda, G., Libonda, L., Chisenga, C. C., Flavien, B. N., Chilyabanyama, O. N., Simunyandi, M., Bosomprah, S., Sande, N. C., Changula, K., Muleya, W., Mburu, M. M., Mubemba, B., Chitanga, S., Tembo, J., Bates, M., Kapata, N., Orba, Y., Kajihara, M., Takada, A., Sawa, H., Chilengi, R., & Simulundu, E. (2021). Mosquito-Borne Viral Pathogens Detected in Zambia: A Systematic Review. Pathogens (Basel, Switzerland), 10(8), . https://doi.org/10.3390/pathogens10081007
Velu, Rachel Milomba, et al. "Mosquito-Borne Viral Pathogens Detected in Zambia: A Systematic Review." Pathogens (Basel, Switzerland) vol. 10,8 (2021). doi: https://doi.org/10.3390/pathogens10081007
Velu RM, Kwenda G, Libonda L, Chisenga CC, Flavien BN, Chilyabanyama ON, Simunyandi M, Bosomprah S, Sande NC, Changula K, Muleya W, Mburu MM, Mubemba B, Chitanga S, Tembo J, Bates M, Kapata N, Orba Y, Kajihara M, Takada A, Sawa H, Chilengi R, Simulundu E. Mosquito-Borne Viral Pathogens Detected in Zambia: A Systematic Review. Pathogens. 2021 Aug 10;10(8). doi: 10.3390/pathogens10081007. PMID: 34451471; PMCID: PMC8401848.
Copy Download .nbib Format: NLM
Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer.

Scientific reports

Yokoi T, Oba T, Kajihara R, Abrams SI, Ito F.
PMID: 34754037
Sci Rep. 2021 Nov 09;11(1):21992. doi: 10.1038/s41598-021-01455-4.

Despite recent progress in therapeutic strategies, prognosis of metastatic triple-negative breast cancer (TNBC) remains dismal. Evidence suggests that the induction and activation of tumor-residing conventional type-1 dendritic cells (cDC1s) is critical for the generation of CD8

Cite
Yokoi T, Oba T, Kajihara R, et al. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Sci Rep. 2021;11(1):21992doi: 10.1038/s41598-021-01455-4.
Yokoi, T., Oba, T., Kajihara, R., Abrams, S. I., & Ito, F. (2021). Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Scientific reports, 11(1), 21992. https://doi.org/10.1038/s41598-021-01455-4
Yokoi, Toshihiro, et al. "Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer." Scientific reports vol. 11,1 (2021): 21992. doi: https://doi.org/10.1038/s41598-021-01455-4
Yokoi T, Oba T, Kajihara R, Abrams SI, Ito F. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Sci Rep. 2021 Nov 09;11(1):21992. doi: 10.1038/s41598-021-01455-4. PMID: 34754037; PMCID: PMC8578367.
Copy Download .nbib Format: NLM
Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise.

International journal of ophthalmology

Kakihara S, Hirano T, Imai A, Kurenuma T, Chiku Y, Murata T.
PMID: 33747814
Int J Ophthalmol. 2021 Mar 18;14(3):388-392. doi: 10.18240/ijo.2021.03.09. eCollection 2021.

AIM: To evaluate the effectiveness of micropulse laser trabeculoplasty (MLT) for eyes with open angle glaucoma (OAG) under maximal tolerable glaucoma eyedrops and to assess the effect of expertise performing MLT on its clinical effectiveness.METHODS: Medical records of 42...

Cite
Kakihara S, Hirano T, Imai A, et al. Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise. Int J Ophthalmol. 2021;14(3):388-392doi: 10.18240/ijo.2021.03.09.
Kakihara, S., Hirano, T., Imai, A., Kurenuma, T., Chiku, Y., & Murata, T. (2021). Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise. International journal of ophthalmology, 14(3), 388-392. https://doi.org/10.18240/ijo.2021.03.09
Kakihara, Shinji, et al. "Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise." International journal of ophthalmology vol. 14,3 (2021): 388-392. doi: https://doi.org/10.18240/ijo.2021.03.09
Kakihara S, Hirano T, Imai A, Kurenuma T, Chiku Y, Murata T. Micropulse laser trabeculoplasty under maximal tolerable glaucoma eyedrops: treatment effectiveness and impact of surgical expertise. Int J Ophthalmol. 2021 Mar 18;14(3):388-392. doi: 10.18240/ijo.2021.03.09. eCollection 2021. PMID: 33747814; PMCID: PMC7930551.
Copy Download .nbib Format: NLM
Early complete response of primary bone marrow B-cell lymphoma treated with rituximab-based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement.

Clinical case reports

Nabe Y, Kikuchi S, Kamihara Y, Wada A, Murakami J, Sato T.
PMID: 34430019
Clin Case Rep. 2021 Aug 16;9(8):e04657. doi: 10.1002/ccr3.4657. eCollection 2021 Aug.

Evaluation of early response by flow cytometry and immunogloblin heavy chain assessments against primary bone marrow B-cell lymphoma could be valuable for predicting treatment outcome.

Cite
Nabe Y, Kikuchi S, Kamihara Y, et al. Early complete response of primary bone marrow B-cell lymphoma treated with rituximab-based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement. Clin Case Rep. 2021;9(8):e04657doi: 10.1002/ccr3.4657.
Nabe, Y., Kikuchi, S., Kamihara, Y., Wada, A., Murakami, J., & Sato, T. (2021). Early complete response of primary bone marrow B-cell lymphoma treated with rituximab-based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement. Clinical case reports, 9(8), e04657. https://doi.org/10.1002/ccr3.4657
Nabe, Yoshimi, et al. "Early complete response of primary bone marrow B-cell lymphoma treated with rituximab-based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement." Clinical case reports vol. 9,8 (2021): e04657. doi: https://doi.org/10.1002/ccr3.4657
Nabe Y, Kikuchi S, Kamihara Y, Wada A, Murakami J, Sato T. Early complete response of primary bone marrow B-cell lymphoma treated with rituximab-based CHOP therapy, assessed by flow cytometry and immunogloblin heavy chain rearrangement. Clin Case Rep. 2021 Aug 16;9(8):e04657. doi: 10.1002/ccr3.4657. eCollection 2021 Aug. PMID: 34430019; PMCID: PMC8365553.
Copy Download .nbib Format: NLM
Showing 445 to 453 of 453 entries